Randomized phase II study of AKT blockade with ipatasertib (GDC-0068) and abiraterone (Abi) vs. Abi alone in patients with metastatic castration-resistant prostate cancer (mCRPC) after docetaxel chemotherapy (A. MARTIN Study).

Abstract

5017Background: mCRPC commonly has hyperactivated PI3K/Akt signaling, usually via PTEN loss; androgen receptor (AR) blockade activates Akt, supporting mCRPC cell survival. We hypothesized that co-i...